The next decade in structural biology
- PMID: 37922863
- DOI: 10.1016/j.str.2023.10.002
The next decade in structural biology
Abstract
As we celebrate the 30th anniversary of Structure, we have asked structural biologists about their expectations on how their respective fields are likely to develop in the next ten years in this collection of Voices.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests P.M.S. is a scientific co-founder and shareholder of Septerna Inc. D.W. is a shareholder of Septerna Inc. P.M.S. and D.W. consult for Septerna Inc. P.M.S. and D.W. are co-founders and shareholders in DACRA Therapeutics. P.M.S. and D.W. receive research funding from the following companies: AstraZeneca, Astex Pharmaceuticals, Boehringer Ingelheim, Dimerix, Novo Nordisk, Pfizer, and Septerna Inc.
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
